Propylhexedrine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Propylhexedrine
- Propylhexedrine: From Nasal Decongestion to Attention Deficit-Hyperactivity Disorder
Propylhexedrine: From Nasal Decongestion to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Propylhexedrine is a volatile sympathomimetic amine that was marketed as an inhalant (BENZEDREX); its only U.S. license on record is now cancelled. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), but 0 clinical trials and 0 publications currently support this direction, so the prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the license record has no approved indication text) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Propylhexedrine is a sympathomimetic amine, structurally related to amphetamine and methamphetamine (a cycloalkyl analog). A plausible link to ADHD would be through catecholamine release or reuptake modulation, which is how established ADHD stimulants work.
This link is speculative. Propylhexedrine is reported to have much weaker central activity than amphetamine, and no mechanism data were available for this report. The argument rests only on structural-class inference and a high model score (0.9997). Misuse potential at high doses is also a safety concern.
Other predicted indications (all L5, no trials or literature):
| Rank | Predicted Indication | Score | Assessment |
|---|---|---|---|
| 2 | Migraine disorder | 99.97% | No mechanistic rationale. Sympathomimetics may trigger headache or raise blood pressure, so benefit is uncertain. |
| 3 | Faciodigitogenital syndrome | 99.96% | Rare genetic developmental disorder. No plausible pharmacological link; likely a network artifact. |
| 4 | Migraine with brainstem aura | 99.95% | Same unsupported rationale as migraine. Vasoconstrictive sympathomimetics are generally a caution in aura-type migraine. |
| 5 | Migraine with or without aura, susceptibility to | 99.94% | A genetic susceptibility locus rather than a treatable phenotype. Likely driven by gene-disease network associations. |
| 6 | Erectile dysfunction | 99.93% | Sympathomimetics typically oppose erection through alpha-adrenergic vasoconstriction, so the pharmacology argues against benefit. |
| 7 | Atrophoderma vermiculata | 99.89% | Rare follicular atrophic skin disorder. No mechanistic connection; appears to be a model artifact. |
| 8 | Ulerythema ophryogenesis | 99.87% | Rare atrophic eyebrow condition. No pharmacological rationale. |
| 9 | Trichotillomania | 99.86% | A catecholaminergic link is conceivable but unsupported, and stimulants may worsen repetitive behaviors. |
| 10 | Tourette syndrome | 99.84% | Stimulant-class sympathomimetics can exacerbate tics, so a therapeutic role is not supported. |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M012 (cancelled) | BENZEDREX | Inhalant | Not available |
The manufacturer was BF Ascher and Co Inc. No valid licenses remain.
Safety Considerations
- Drug Interactions: No interaction records were found for this drug.
- Misuse potential: Propylhexedrine is reported to carry a misuse risk at high doses.
- Class cautions: Sympathomimetics may raise blood pressure, may exacerbate tics (relevant to Tourette syndrome), and are generally a caution in aura-type migraine.
Please refer to the package insert for the full safety information, including warnings and contraindications. These were not available for this report and need to be obtained before any safety screening.
Conclusion and Next Steps
Decision: Hold
Rationale: The predictions rest only on model scores. There are no clinical trials or publications, no mechanism of action data, and the only U.S. license is cancelled. The ADHD link is plausible only through structural similarity to amphetamine, and the other predictions are mostly implausible or pharmacologically contradicted.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, particularly central catecholaminergic activity compared with amphetamine
- A literature and trial search focused on ADHD, to test whether any supporting evidence exists
- An assessment of misuse and abuse liability
- Route and formulation compatibility analysis (an inhalant product versus the oral route typically used for ADHD)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.